<< Back To Authors

Overview

Liz Highleyman

Liz is Science Editor for Cancer Health, POZ, Hep and Real Health. She has been a health journalist and medical editor for more than 20 years, covering HIV, viral hepatitis, cancer and other health issues.

Articles

Two-Drug Regimen Works Well for People With Advanced HIV

Additional data show Dovato (dolutegravir/lamivudine) is also a feasible option when drug-resistance testing is unavailable.

Prevention: HIV Risk for Women

The team identified 14 species of vaginal bacteria linked to HIV acquisition.

Twice-Yearly PrEP Works Well for Gay Men

But this promise can only be realized if lenacapavir PrEP is available to those who need it most.

DHHS Updates HIV Guidelines

The guidelines also feature updated recommendations for older people living with HIV, transgender people and more.

Cure: CRISPR Gene Therapy

Findings suggest CRISPR-based therapies might play a role in a combination functional cure strategy

Pain Management Program for People With HIV

A majority of people with HIV experience persistent pain, which can lead to disability and difficulty adhering to antiretroviral treatment.

Treatment: Drug Resistance

Findings suggest that switching to Dolutegravir/lamivudine could be a cost-saving approach, especially in lower-income countries.

People Living With HIV Have Unmet Needs

Physical and mental health, subsistence needs and stigma can all affect quality of life for people living with HIV.

Hot topics

Forums: Support and discussion

Blogs: The community speaks

POZ Stories: Get inspired

Magazine: Search the archives

HIV: The Basics

Recursos de VIH/SIDA en Español

AIDS Is Everyday

Ask POZ

Concerns: COVID Evolution

Being on antiretroviral treatment and maintaining an undetectable HIV viral load is key to avoiding prolonged and severe COVID.

Weekly Oral HIV Treatment Continues to Look Promising

A once-weekly combination of lenacapavir and islatravir pills maintained viral suppression for 48 weeks.

Dapivirine vaginal ring on blue gloved hand

3-Month Vaginal Ring Could Offer Longer-Lasting Protection Against HIV

Some women prefer the ring even though it’s less effective than daily PrEP pills or long-acting injections.

Twice-Yearly Lenacapavir PrEP Highly Effective in Second Study

Results for gay men and gender-diverse people confirm stellar HIV prevention findings for women reported this summer.

Description 3D rendering of a compass with the word guidelines

Department of Health and Human Services Updates HIV Guidelines

Revised recommendations address antiretroviral treatment strategies, comorbidities and special populations.

Needs of Older People With HIV Are Going Unmet

The U.S. is not on track to meet 2025 goals for self-rated health, mental health services, employment, adequate food or stable housing.

vial and needle vaccine injection medication

ViiV Will Triple Annual Supply of Long-Acting PrEP for Low and Middle-Income Countries

At least 2 million doses of Apretude will be made available to meet growing demand where unmet need is greatest.

Gilead Signs Voluntary Licensing Agreements for Lenacapavir PrEP

Advocates welcome the agreement, but some say it should not be limited only to lower-income countries.